Mayo Clinic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mayo Clinic sits in the top decile of US sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count).
Mayo Clinic: 2,844 sponsored US clinical trials, 544 recruiting.
Mayo Clinic sponsors 2,844 registered US clinical trials on ClinicalTrials.gov, 544 of them currently recruiting, and 1,816 completed. 252 of these trials are in Phase 3-4 (later-stage) and 821 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 36 trials.
Top-decile sponsor footprint
Mayo Clinic ranks in the top decile of sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,844 total, page 37 of 57
Proof of Concept: "Bottom's Up" Seat to Treat Constipation
NCT02419924
Mindfulness Based Resilience Training
NCT02419430
Pilot Study Testing Feasibility of Health Screening at Farm Site
NCT02418637
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
NCT02364713
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01806571
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT02282930
Optimizing the Management of Flares in Patients With Rheumatoid Arthritis (RA)
NCT02382783
Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery
NCT02356198
Biomarker Feedback to Motivate Cessation in Pregnancy
NCT02431611
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression
NCT02389712
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
NCT02332980
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
NCT02320292
A PK/PD Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression
NCT02286440
Gut Permeability, Sensitivity and Symptomatology
NCT02358564
Optimizing Sleep/Wake Related Cognitive Efficacy
NCT02412410
Early Diuresis Following Colorectal Surgery
NCT02351934
Shared Decision Making With Pharmaceutical Care
NCT02373059
Fostering Resilience in Physician Moms
NCT02540473
Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma
NCT02274519
Electronic Nose Identification of Fasting and Non-fasting Breath Profiles
NCT02419976
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
NCT02320305
Microbreaks in the OR to Mitigate High Physical and Mental Demands
NCT02565394
Statin Choice Decision Aid Implementation First Phase
NCT02375815
The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis
NCT02353078
Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)
NCT01978535
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
NCT02089217
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
NCT02219789
Microbiome of Depression & Treatment Response to Citalopram
NCT02330068
Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women
NCT02272647
Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
NCT02330094
New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease
NCT02250287
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
NCT02265341
Nurse-led Patient-centered Advance Care Planning: A Pilot Study
NCT02302820
Estradiol-Receptor Blockade in Older Men and Women
NCT02271282
Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study
NCT02318433
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT02283658
Short Versus Long Cephalomedullary Nailing of Pertrochanteric Hip Fractures: A Randomized Prospective Study
NCT02285127
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression
NCT02189057
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
NCT02285634
Development of a Youth Healthy Living Program With Underserved Adolescents at Rochester Alternative Learning Center
NCT02289313
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
NCT02197767
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
NCT02266394
Study of Exparel Versus Epidural for Pain Control After Thoracotomy
NCT02178553
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
NCT02616211
CIMT and Plaque Assessment Findings in Subjects Undergoing Stress Echocardiography For Risk Stratification
NCT02245048
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
NCT02234336
Pilot Project on External Vestibular Prosthesis in Chronic Subjective Dizziness
NCT02048670
Home Telemonitoring in Patients at High Risk for Readmission
NCT02136186
Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
NCT02262078
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
NCT02249169
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 435 |
| Phase 2 | 386 |
| Phase 3 | 86 |
| Phase 4 | 166 |
Therapeutic Areas
What is open in the Mayo Clinic pipeline
544 recruiting of 2,844 indexed (19% open); 1,816 completed (64%).
Phase mix: 252 late (III/IV) vs 821 early (I/II) (early-phase heavy).
Top condition: Healthy (36 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.